FDA amends opioid action warning

Share this article:
The Food and Drug Administration will temporarily allow the continued production, marketing and distribution of one particular type of opioid, which is widely used to alleviate pain in terminally ill patients.

The action is in response to a March 30 warning that it issued to manufacturers to stop producing certain unapproved prescription opioids.  Concerns from palliative care patients and healthcare professionals prompted the FDA to amend the warning. They were concerned that the original order would cause a shortage of morphine sulfate oral solution.

The agency has determined that the 20 milligram dosage form of morphine sulfate oral solution is medically necessary and should remain on the market until an approved alternative becomes available.

Share this article:

More in News

A small team of workers responds best in emergencies, expert says

A small team of workers responds best in ...

Long-term care providers should consider a "flat" crisis management approach that relies on a core group of staff members, experts advised Wednesday at the LeadingAge annual conference.

Nursing homes have better pain and catheter management if leaders have more ...

Nursing homes led by administrators and directors of nursing with higher levels of education and certification have better outcomes on some key quality measures, according to recently published findings.

Court green-lights charges that a healthcare network underused observation stays

A whistleblower can continue to pursue charges that a Nevada healthcare network routinely admitted people as hospital inpatients when they should have been placed in observation status, a federal appeals court recently ruled.